- WuXi AppTec has signed two memoranda of understanding (MoUs) with NEOM and the Saudi Ministry of Health to explore localising pharmaceutical R&D and manufacturing.
- The agreements aim to support Saudi Arabia’s biotechnology ambitions and develop a skilled pharmaceutical workforce.
WuXi AppTec, a global pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO), has signed two strategic memoranda of understanding (MoUs) with NEOM and the Ministry of Health of the Kingdom of Saudi Arabia (MOH).
Under the MoU with NEOM, WuXi AppTec will collaborate to explore the localisation of pharmaceutical research, development, and manufacturing in Saudi Arabia. The agreement establishes the foundation for developing world-class CRDMO facilities at Oxagon—NEOM’s advanced and clean manufacturing city—or other sites across the country.
The collaboration combines WuXi AppTec’s experience in global contract manufacturing and development with NEOM’s focus on sustainability and innovation. It aims to strengthen the country’s biotechnology sector and foster a forward-looking pharmaceutical ecosystem.
The MoU with the Ministry of Health will focus on developing a large-scale pharmaceutical workforce, localising the pharmaceutical value chain, and attracting foreign direct investment to the Kingdom.
According to WuXi AppTec, these agreements align with its mission to support global partners in discovering, developing, and manufacturing pharmaceuticals and healthcare products for patients worldwide, while contributing to the broader MENA region’s healthcare goals.
